Molecular targets for radiation therapy: Bringing preclinical data into clinical trials

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3518-3520

  Tofilon, Philip J ^a   Saxman, Scott ^a   Coleman, C Norman ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CANCER RADIOTHERAPY; DATA ANALYSIS; DNA REPAIR; EDITORIAL; GROWTH INHIBITION; IONIZING RADIATION; MOLECULAR EVOLUTION; PRIORITY JOURNAL; RADIOSENSITIVITY; TISSUE INJURY; TUMOR GROWTH;

CLINICAL TRIALS; DRUG DESIGN; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0141791360     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Begg, A. C., and Vens, C. Genetic manipulation of radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys., 49: 367-371, 2001.
2. Coleman, C. N. International Conference on Translational Research and Preclinical Strategies in Radio-Oncology (ICTR)-conference summary. Int. J. Radiat. Oncol. Biol. Phys., 49: 301-309, 2001.
3. Brown, J. M. Therapeutic targets in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 49: 319-326, 2001.
4. Dent, P., Yacoub, A., Contessa, J., Caron, R., Amorino, G., Valerie, K., Hagan, M. P., Grant, S., and Schmidt-Ullrich, R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat. Res., 159: 283-300, 2003.
5. Steel, G. G., and Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5: 85-91, 1979.
6. Colevis, A. D., Brown, J. M., Hahn, S., Mitchell, J., Camphausen, K., and Coleman, C. N. Development of investigational radiation modifiers. J. Natl. Cancer Inst. (Bethesda), JNCI 9: 646-651, 2003.
7. She, Y., Lee, F., Chen, J, Haimovitz-Friedman, A., Miller, V. A., Rusch, V. R., Kris, M. G., and Sirotnak, F. M. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin. Cancer Res., 9: 3773-3778, 2003.
8. Harari, P. M., and Huang, S. M. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin. Radiat. Oncol., 12 (Suppl. 2): 21-26, 2002.
9. Huang, S-M., Li, J., Armstrong, E. A., and Harari, P. M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res., 62: 4300-4306, 2002.
10. Solomon, B., Hagekyriakou, J., Trivett, M. K., Stacker, S. A., McArthur, G. A., and Cullinane, C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int. J. Radiat. Oncol. Biol. Phys., 55: 713-723. 2003.
11. Sartor, C. I. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin. Radiat. Oncol., 13: 22-30, 2003.
12. Milas, L., Mason, K., Hunter, N., Petersen, S., Yamakawa, M., Ang, K., Mendelsohn, J., and Fan, Z. In vivo enhancement of tumor radio-response by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res., 6: 701-708, 2000.
13. Travis, E. L. The sequence of histological changes in mouse lungs after single doses of x-rays. Int. J. Radiat. Oncol. Biol. Phys., 6: 345-347, 1980.
14. Tucker, S. L., and Travis, E. L. Time course for the hazard of radiation-induced pneumonitis death in mice. Int. J. Radiat. Biol., 62: 627-639, 1992.
15. Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., and Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer. Res., 6: 4885-4892, 2000.
16. Eberhard, D. A., Huntzicker, E., and Anderson, S. Epidermal growth factor receptor immunohistochemistry: assay selection and application to breast cancers. Proc. Am. Soc. Clin. Oncol., 21: 448a, 2002.